Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
The impressive improvement of overall survival in multiple myeloma (MM) patients in the last years has been mostly related to the availability of new classes of drugs with different mechanisms of action, including proteasome inhibitors (PI), immunomodulating agents (IMiDs), and monoclonal antibodies...
Saved in:
Main Authors: | Gregorio Barilà (Author), Rita Rizzi (Author), Renato Zambello (Author), Pellegrino Musto (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bispecific antibodies for non-Hodgkin's lymphomas and multiple myeloma
by: Omar Castaneda-Puglianini, et al.
Published: (2021) -
Bispecific antibodies in cancer immunotherapy
by: Eva Dahlén, et al.
Published: (2018) -
Bispecific antibodies for viral immunotherapy
by: Elisabeth K. Nyakatura, et al.
Published: (2017) -
The Importance of Alliance between Hematologists and Dentists: A Retrospective Study on the Development of Bisphosphonates Osteonecrosis of the Jaws (Bronj) in Multiple Myeloma Patients
by: Christian Bacci, et al.
Published: (2021) -
Bispecific antibody treatment of multiple myeloma: latest updates from the 2022 ASH annual meeting
by: Xuejiao Yin, et al.
Published: (2023)